Maze Therapeutics, Inc. Common Stock

MAZENASDAQUSD
28.20 USD
1.38 (4.67%)🟢LIVE (AS OF 09:33 AM EDT)
🟢Market: OPEN

MAZE is currently priced at $28.20. The technical outlook is "Neutral" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Aug 26, 2026.

Open?$29.61
High?$29.61
Low?$27.83
Prev. Close?$29.58
Volume?18.7K
Avg. Volume?359.0K
VWAP?$28.15
Rel. Volume?0.05x
Bid / Ask
Bid?$20.63 × 100
Ask?$33.99 × 100
Spread?$13.36
Midpoint?$27.31
Valuation & Ratios
Market Cap?1.6B
Shares Out?55.5M
Float?43.1M
Float %?77.9%
P/E Ratio?N/A
P/B Ratio?3.63
EPS?-$2.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Employees
141
Market Cap
1.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2025-01-31
Address
171 OYSTER POINT BOULEVARD, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 850-5070
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
77
Short Sent.?
23
Piotroski F-Score?0/9Weak
Altman Z-Score?11.12Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?13.89%High
Short Interest?6.0M
Days to Cover?16.2
Free Float43.1M
Avg Daily Volume370.3K
Settlement Date2026-08-14
Financial Health
Current Ratio?18.31Strong
Quick Ratio?18.31Strong
Cash Ratio?8.83Strong
Debt/Equity?0.09Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A
P/B?
Peers
100
S&P
48
3.63FAIR
P/S?
Peers
100
S&P
3
82.16HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-10.3CHEAP
EV/Sales?
Peers
100
S&P
3
73.97HIGH
Returns & Efficiency
ROE?
S&P
6
-29.5%WEAK
ROA?
S&P
3
-25.1%WEAK
Cash Flow & Enterprise
FCF?$-106840000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day